公司资料
Scholar Rock 股价、新闻与催化剂
- 股票代码:
- SRRK
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
52.05 USD (-0.89%)
收盘价
最后更新: 2026年8月17日
5.35B USD
市值
股价为何变动
The latest company update was “Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)”. SRRK changed 0.89% and closed at $52.05 on Aug 17, 2026, indicating a relatively limited closing-price reaction to this company update.
公司概览
Myostatin Biology
Scholar Rock develops therapies that selectively modulate growth factors in their latent forms. Its lead work targets myostatin to improve muscle function while preserving related signaling pathways.
Apitegromab
Apitegromab is a selective inhibitor of latent myostatin under FDA review for children and adults with spinal muscular atrophy. It is designed as an add-on to therapies that address the underlying genetic cause.
Additional Pipeline
Scholar Rock is applying its platform to additional neuromuscular and metabolic indications where modulation of muscle biology may provide clinical benefit.
未来催化剂
- FDA action on the apitegromab BLA by September 30, 2026.
- Potential U.S. launch of apitegromab immediately following approval.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。